RESUMO
BACKGROUNDThe worldwide COVID-19 pandemic is increasing exponentially and demands an effective and promising therapy at most emergency. METHODSWe have assembled a cohort consisting 504 hospitalized COVID-19 patients. Detailed information on patients characteristics and antiviral medication use during their stay at designated hospitals along with their pre and post treatment results were collected. The study objective is to evaluate the treatment efficacy of Arbidol, together with the concurrent drugs Oseltamivir and Lopinavir/Ritonavir on mortality and lesion absorption based on chest CT scan. FINDINGSThe overall mortality rate was 15.67% in the cohort. The older age, lower SpO2 level, larger lesion, early admission date, and the presence of pre-existing conditions were associated with higher mortality. After adjusting for the patients age, sex, pre-existing condition, SpO2, lesion size, admission date, hospital, and concurrent antiviral drug use, Arbidol was found promising and associated with reduced mortality. The OR for Arbidol is 0{middle dot}183 (95% CI, 0{middle dot}075 to 0{middle dot}446; P<0{middle dot}001). Furthermore, Arbidol is also associated with faster lesion absorption after adjusting for patients characteristics and concurrent antiviral drug use (P=0{middle dot}0203). INTERPRETATIONThe broad-spectrum antiviral drug Arbidol was found to be associated with faster
RESUMO
BackgroundWuhan, China was the epicenter of the 2019 coronavirus outbreak. As a designated hospital, Wuhan Pulmonary Hospital has received over 700 COVID-19 patients. With the COVID-19 becoming a pandemic all over the world, we aim to share our epidemiological and clinical findings with the global community. MethodsIn this retrospective cohort study, we studied 340 confirmed COVID-19 patients from Wuhan Pulmonary Hospital, including 310 discharged cases and 30 death cases. We analyzed their demographic, epidemiological, clinical and laboratory data and implemented our findings into an interactive, free access web application. FindingsBaseline T lymphocyte Subsets differed significantly between the discharged cases and the death cases in two-sample t-tests: Total T cells (p < 2{middle dot}2e-16), Helper T cells (p < 2{middle dot}2e-16), Suppressor T cells (p = 1{middle dot}8-14), and TH/TS (Helper/Suppressor ratio, p = 0{middle dot}0066). Multivariate logistic regression model with death or discharge as the outcome resulted in the following significant predictors: age (OR 1{middle dot}05, p 0{middle dot}04), underlying disease status (OR 3{middle dot}42, p 0{middle dot}02), Helper T cells on the log scale (OR 0{middle dot}22, p 0{middle dot}00), and TH/TS on the log scale (OR 4{middle dot}80, p 0{middle dot}00). The McFadden pseudo R-squared for the logistic regression model is 0{middle dot}35, suggesting the model has a fair predictive power. InterpretationWhile age and underlying diseases are known risk factors for poor prognosis, patients with a less damaged immune system at the time of hospitalization had higher chance of recovery. Close monitoring of the T lymphocyte subsets might provide valuable information of the patients condition change during the treatment process. Our web visualization application can be used as a supplementary tool for the evaluation. FundingThe authors report no funding.
RESUMO
In subjects aged above 40 years old in Pudong,Shanghai,the annual progression rates from normal glucose regulation to impaired glucose tolerance and to diabetes were 9.5%and 4.4%respectively.and the annual progression rate in subjects with impaired Slucose regulation to diabetes was 20.2%.The conversion rate to diabetes increased along with elevated number of risk factors.
